Bionano Genomics (NASDAQ:BNGO) Stock Lifted to “Hold” by Wall Street Zen

Wall Street Zen upgraded shares of Bionano Genomics (NASDAQ:BNGO) to a hold rating in a research report released on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings raised Bionano Genomics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday, September 2nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $6.00.

Bionano Genomics Stock Down 1.8%

BNGO opened at $1.66 on Friday. The company has a quick ratio of 1.96, a current ratio of 2.48 and a debt-to-equity ratio of 0.11. The stock has a market cap of $19.55 million, a price-to-earnings ratio of -0.55 and a beta of 1.65. Bionano Genomics has a twelve month low of $1.00 and a twelve month high of $2.23. The company’s 50-day moving average price is $1.26 and its two-hundred day moving average price is $1.22.

Bionano Genomics (NASDAQ:BNGO) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.03. The company had revenue of ($6.67) million during the quarter, compared to analyst estimates of $7.55 million. Bionano Genomics had a negative net margin of 106.58% and a negative return on equity of 78.78%. As a group, equities analysts expect that Bionano Genomics will post -2.49 earnings per share for the current year.

Hedge Funds Weigh In On Bionano Genomics

An institutional investor recently bought a new stake in Bionano Genomics stock. GSA Capital Partners LLP purchased a new stake in Bionano Genomics, Inc. (NASDAQ:BNGO) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 150,284 shares of the company’s stock, valued at approximately $170,000. GSA Capital Partners LLP owned 1.31% of Bionano Genomics as of its most recent SEC filing. Institutional investors own 11.35% of the company’s stock.

About Bionano Genomics

Bionano Genomics, Inc is a life sciences company that develops genomic analysis technologies designed to identify structural variation and other genetic abnormalities that may be difficult to detect with conventional sequencing methods. The company’s platform is used in research, clinical, and pharmaceutical applications, including studies of cancer, inherited disease, and genome biology.

Its primary product is the Saphyr system, an optical genome mapping platform that analyzes long, fluorescently labeled DNA molecules as they pass through nanochannel arrays.